Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

GenVec 2011 net loss decreases to $7.4 million

Today GenVec, Inc. announced financial results for the fourth quarter and year ended December 31, 2011. For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010.

15 Mar 2012

Asahi Kasei to acquire ZOLL

Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.

12 Mar 2012

Common sexually transmitted bacterial infection more than doubles risk of HIV

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, according to a study by researchers at RTI International.

11 Mar 2012

Infection with M. genitalium may double African women's HIV risk

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, reports a study in the March issue of AIDS.

9 Mar 2012

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012

Europe conference to discuss on new HIV indicator diseases

Today, heterosexuals in Europe are at particular risk of carrying HIV for so long that they remain undiagnosed until their immune system starts to fail and they become ill. An international study under the leadership of the HIV in Europe initiative has now revealed that a number of diseases, including herpes zoster and certain forms of cancer, should be on the list of indicators for having HIV - and thus serve to prompt health care professionals to suggest an HIV-test to their patients.

2 Mar 2012

NEJM publishes results from two Jakafi Phase III studies on MF

The New England Journal of Medicine (NEJM) today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis.

1 Mar 2012

Valeant receives FDA approval for secondary supplier of Methoxsalen

The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.

15 Feb 2012

SAMHD1 protein cuts off raw material that HIV needs to create DNA and replicate

A protein that protects some of our immune cells from the most common and virulent form of HIV works by starving the virus of the molecular building blocks that it needs to replicate, according to research published online in Nature Immunology.

13 Feb 2012

GSK launches Medivir's Xerclear for OTC use in Europe

Medivir AB, the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe.

8 Feb 2012

Tips to avoid infections during Valentine's Day

Say "I love you" with flowers, chocolates or a greeting card, but be careful when you kiss this Valentine's Day. "Mid-February is usually the peak season for infectious diseases, such as the seasonal and H1N1 flu, mononucleosis, colds and coughs," says Jorge Parada, MD, medical director, infectious disease at Loyola University Health System. "And don't rely on obvious signs of illness - such as sneezing or fever as a tip off. People with infectious diseases start shedding the virus before they experience the full effect of the illness."

2 Feb 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

HPV transmission via oral sex practices suggests research

A new study suggested that an estimated 7% of American teens and adults carry the human papillomavirus in their mouths. This may help health experts finally understand why rates of mouth and throat cancer have been climbing for nearly 25 years. The evidence additionally makes it clear that oral sex practices play a key role in transmission.

29 Jan 2012

Shortages of anti-infective drugs can put patients at risk and alter clinical care

Shortages of key drugs used to fight infections represent a public health emergency and can put patients at risk, according to a review published in Clinical Infectious Diseases and available online.

20 Jan 2012

New NIST clinical SRM can help in accurate CMV detection and treatment

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

12 Jan 2012

Study confirms condom use reduces risk of HIV infection by 78%

The level of HIV-1 in the blood of an HIV-infected partner is the single most important factor influencing risk of sexual transmission to an uninfected partner, according to a multinational study of heterosexual couples in sub-Saharan Africa.

12 Jan 2012

Starpharma receives FDA Special Protocol Assessment for bacterial vaginosis phase 3

Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

10 Jan 2012

Investigational HSV vaccine shows promise against two genital herpes diseases

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause genital herpes, according to findings in the New England Journal of Medicine.

5 Jan 2012

UV rays help prevent spread of chickenpox

Ultraviolet rays help prevent the spread of chickenpox, meaning people in milder climates are more at risk of catching the disease, according to new research. The discovery could lead to new ways of preventing chickenpox and its more severe relative, shingles.

16 Dec 2011

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

Incyte Corporation today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting.

13 Dec 2011